Monimus Capital Management LP Acquires Shares of 137,058 Roivant Sciences Ltd. (NASDAQ:ROIV)

Monimus Capital Management LP purchased a new stake in shares of Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 137,058 shares of the company's stock, valued at approximately $1,621,000. Roivant Sciences comprises about 1.5% of Monimus Capital Management LP's holdings, making the stock its 25th biggest position.

Other institutional investors have also modified their holdings of the company. Monaco Asset Management SAM grew its stake in Roivant Sciences by 35.0% during the 4th quarter. Monaco Asset Management SAM now owns 135,000 shares of the company's stock worth $1,597,000 after buying an additional 35,000 shares during the last quarter. Commonwealth Equity Services LLC grew its stake in shares of Roivant Sciences by 24.2% during the fourth quarter. Commonwealth Equity Services LLC now owns 19,588 shares of the company's stock worth $232,000 after acquiring an additional 3,813 shares during the last quarter. Thompson Siegel & Walmsley LLC increased its holdings in shares of Roivant Sciences by 10.1% during the fourth quarter. Thompson Siegel & Walmsley LLC now owns 565,337 shares of the company's stock valued at $6,688,000 after acquiring an additional 51,705 shares in the last quarter. Swiss National Bank raised its position in shares of Roivant Sciences by 0.9% in the 4th quarter. Swiss National Bank now owns 727,246 shares of the company's stock valued at $8,603,000 after purchasing an additional 6,200 shares during the last quarter. Finally, Avantax Advisory Services Inc. acquired a new stake in Roivant Sciences in the 4th quarter worth approximately $127,000. 64.76% of the stock is currently owned by institutional investors.

Remove Ads

Insider Buying and Selling at Roivant Sciences

In other Roivant Sciences news, COO Eric Venker sold 100,000 shares of the company's stock in a transaction on Friday, December 20th. The shares were sold at an average price of $11.49, for a total transaction of $1,149,000.00. Following the completion of the transaction, the chief operating officer now directly owns 595,580 shares in the company, valued at approximately $6,843,214.20. This represents a 14.38 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CAO Rakhi Kumar sold 227,500 shares of Roivant Sciences stock in a transaction dated Thursday, February 13th. The shares were sold at an average price of $10.43, for a total transaction of $2,372,825.00. Following the completion of the sale, the chief accounting officer now owns 163,264 shares in the company, valued at approximately $1,702,843.52. This trade represents a 58.22 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 2,388,170 shares of company stock valued at $27,612,299. Company insiders own 7.90% of the company's stock.

Analysts Set New Price Targets

A number of research firms have issued reports on ROIV. Cantor Fitzgerald raised shares of Roivant Sciences to a "strong-buy" rating in a report on Tuesday, March 4th. HC Wainwright reaffirmed a "buy" rating and set a $18.00 price target on shares of Roivant Sciences in a research report on Tuesday, February 11th. One research analyst has rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Buy" and a consensus price target of $18.08.

Roivant Sciences Price Performance

NASDAQ:ROIV traded down $0.14 during trading hours on Tuesday, reaching $10.71. The company had a trading volume of 3,638,684 shares, compared to its average volume of 5,496,485. The firm has a market cap of $7.64 billion, a PE ratio of -71.40 and a beta of 1.26. Roivant Sciences Ltd. has a 1-year low of $9.76 and a 1-year high of $13.06. The business's 50 day moving average price is $10.78 and its 200-day moving average price is $11.48.

Roivant Sciences (NASDAQ:ROIV - Get Free Report) last announced its quarterly earnings results on Monday, February 10th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.24) by $0.04. Roivant Sciences had a negative net margin of 119.54% and a negative return on equity of 14.05%. On average, analysts expect that Roivant Sciences Ltd. will post -0.92 earnings per share for the current fiscal year.

Roivant Sciences Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.